Analysts at Citi and Bank of America (NYSE:BAC) are maintaining a cautious stance on Hims & Hers Health as competition in the GLP-1 space intensifies and growth begins to moderate.

Today is a big day in drugs. It’s when the US Food and Drug Administration shuts down an emergency measure that allows pharmacies to sell copies of the most widely prescribed weight-loss injection.

Amid volatile trade and rising uncertainty, these momentum stocks have shown strong signs of leadership in the first half of ...

A number of stocks fell in the afternoon session after the major pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury ...

This week’s picks cover: why Hims & Hers Health’s personalised healthcare platform has huge operating leverage, how Jumbo Interactive’s strong fundamentals and profitability provide solid income and ...

Hims & Hers Health HIMS is well-positioned for growth as it addresses a vast unmet healthcare market, leveraging a total addressable market of $360M across specialties like mental health, weight loss ...

Earning 5% back at both Amazon (which basically sells everything) and Whole Foods is unbeatable, but you can't get this card without an Amazon Prime membership. Many or all of the products on this ...

There's a well-known saying in the investing world, which advises investors to "sell in May and go away." Historically, that ...